ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1579699
This article is part of the Research TopicTherapeutic Effects of Endogenous Hormones in Pathologies Linked to Metabolic and/or Inflammatory DisordersView all 5 articles
URINARY URODILATIN LEVELS IN PATIENTS WITH RENAL SALT WASTING SYNDROME AS A POSSIBLE NEW DIAGNOSTIC MARKER. A PILOT STUDY
Provisionally accepted- 1University of Palermo, Palermo, Italy
- 2IRCCS Ca' Granda Ospedale Maggiore, Milano, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
BACKGROUND: Renal Salt Wasting Syndrome (RSW) is a clinical syndrome with laboratory characteristics completely overlapping with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). No studies have yet investigated the potential role of urodilatin as a diagnostic marker or its involvement in the pathogenesis of RSW.METHODS: We performed a retrospective observational case-control study, the patients were divided into 3 groups: a group of hyponatremic patients with RSW (cases) and two control groups (subjects without hyponatremia and subjects with hyponatremia from other causes). Main outcomes were assessing the differences in urinary urodilatin values in patients with RSW compared to both control groups and to evaluate the diagnostic power of urodilatin with the analysis of ROC curves.RESULTS: Patients with RSW display significantly higher mean urodilatin levels than both patients with (median 5.46 vs 0.57 ng/mL, p=0.006) or without hyponatremia (median 5.46 vs 0.27 ng/mL, p<0.001). Diagnostics performances of mean urodilatin levels for RSW diagnosis were evaluated by ROC curve, AUC was 0.94 (95%CI 0.86-1.00). CONCLUSIONS: This case-control study has shown interesting results regarding the dosage of urinary urodilatin in patients with RSW, with potentially clarifying implications both regarding the pathogenesis of this syndrome and regarding the diagnosis and therefore the clinical management of patients.
Keywords: Renal salt wasting syndrome, Urodilatin, ANP, natriuretic peptide, Hyponatremia
Received: 19 Feb 2025; Accepted: 09 May 2025.
Copyright: © 2025 Della Corte, Agnello, Norrito, Cataldi, Vidali, Pecoraro, Maida, Lo Sasso, Giglio, Ciaccio and Tuttolomondo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Vittoriano Della Corte, University of Palermo, Palermo, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.